874 related articles for article (PubMed ID: 15625712)
1. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
Covaceuszach S; Cattaneo A; Lamba D
Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
[TBL] [Abstract][Full Text] [Related]
2. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic structural disorder of mouse proNGF.
Paoletti F; Covaceuszach S; Konarev PV; Gonfloni S; Malerba F; Schwarz E; Svergun DI; Cattaneo A; Lamba D
Proteins; 2009 Jun; 75(4):990-1009. PubMed ID: 19089979
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor.
Wiesmann C; Ultsch MH; Bass SH; de Vos AM
Nature; 1999 Sep; 401(6749):184-8. PubMed ID: 10490030
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the binding of an anti-cytochrome c antibody to its antigen: crystal structures of FabE8-cytochrome c complex to 1.8 A resolution and FabE8 to 2.26 A resolution.
Mylvaganam SE; Paterson Y; Getzoff ED
J Mol Biol; 1998 Aug; 281(2):301-22. PubMed ID: 9698550
[TBL] [Abstract][Full Text] [Related]
6. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.
Ugolini G; Marinelli S; Covaceuszach S; Cattaneo A; Pavone F
Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2985-90. PubMed ID: 17301229
[TBL] [Abstract][Full Text] [Related]
7. The crystal structure of the pathogenic collagen type II-specific mouse monoclonal antibody CIIC1 Fab: structure to function analysis.
Uysal H; Sehnert B; Nandakumar KS; Böiers U; Burkhardt H; Holmdahl R; Thunnissen MM
Mol Immunol; 2008 Apr; 45(8):2196-204. PubMed ID: 18241923
[TBL] [Abstract][Full Text] [Related]
8. Cross-reactive binding of cyclic peptides to an anti-TGFalpha antibody Fab fragment: an X-ray structural and thermodynamic analysis.
Hahn M; Winkler D; Welfle K; Misselwitz R; Welfle H; Wessner H; Zahn G; Scholz C; Seifert M; Harkins R; Schneider-Mergener J; Höhne W
J Mol Biol; 2001 Nov; 314(2):293-309. PubMed ID: 11718562
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of a peptide complex of anti-influenza peptide antibody Fab 26/9. Comparison of two different antibodies bound to the same peptide antigen.
Churchill ME; Stura EA; Pinilla C; Appel JR; Houghten RA; Kono DH; Balderas RS; Fieser GG; Schulze-Gahmen U; Wilson IA
J Mol Biol; 1994 Aug; 241(4):534-56. PubMed ID: 7520084
[TBL] [Abstract][Full Text] [Related]
10. Immunological determinants of nerve growth factor involved in p140trk (Trk) receptor binding.
Nanduri J; Vroegop SM; Buxser SE; Neet KE
J Neurosci Res; 1994 Mar; 37(4):433-44. PubMed ID: 7517456
[TBL] [Abstract][Full Text] [Related]
11. Dissecting NGF interactions with TrkA and p75 receptors by structural and functional studies of an anti-NGF neutralizing antibody.
Covaceuszach S; Cassetta A; Konarev PV; Gonfloni S; Rudolph R; Svergun DI; Lamba D; Cattaneo A
J Mol Biol; 2008 Sep; 381(4):881-96. PubMed ID: 18635195
[TBL] [Abstract][Full Text] [Related]
12. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
Julien JP; Bryson S; Nieva JL; Pai EF
J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
[TBL] [Abstract][Full Text] [Related]
13. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors.
Wehrman T; He X; Raab B; Dukipatti A; Blau H; Garcia KC
Neuron; 2007 Jan; 53(1):25-38. PubMed ID: 17196528
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.
Darbha R; Phogat S; Labrijn AF; Shu Y; Gu Y; Andrykovitch M; Zhang MY; Pantophlet R; Martin L; Vita C; Burton DR; Dimitrov DS; Ji X
Biochemistry; 2004 Feb; 43(6):1410-7. PubMed ID: 14769016
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: conformational influence of an engineered disulfide bond.
Almog O; Benhar I; Vasmatzis G; Tordova M; Lee B; Pastan I; Gilliland GL
Proteins; 1998 May; 31(2):128-38. PubMed ID: 9593187
[TBL] [Abstract][Full Text] [Related]
16. Identification and structure of the nerve growth factor binding site on TrkA.
Robertson AG; Banfield MJ; Allen SJ; Dando JA; Mason GG; Tyler SJ; Bennett GS; Brain SD; Clarke AR; Naylor RL; Wilcock GK; Brady RL; Dawbarn D
Biochem Biophys Res Commun; 2001 Mar; 282(1):131-41. PubMed ID: 11263982
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing epitopes on the extracellular interferon gamma receptor (IFNgammaR) alpha-chain characterized by homolog scanning mutagenesis and X-ray crystal structure of the A6 fab-IFNgammaR1-108 complex.
Sogabe S; Stuart F; Henke C; Bridges A; Williams G; Birch A; Winkler FK; Robinson JA
J Mol Biol; 1997 Nov; 273(4):882-97. PubMed ID: 9367779
[TBL] [Abstract][Full Text] [Related]
18. Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607.
Teplyakov A; Obmolova G; Wu SJ; Luo J; Kang J; O'Neil K; Gilliland GL
J Mol Biol; 2009 May; 389(1):115-23. PubMed ID: 19361524
[TBL] [Abstract][Full Text] [Related]
19. An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope.
Li Y; Parry G; Chen L; Callahan JA; Shaw DE; Meehan EJ; Mazar AP; Huang M
J Mol Biol; 2007 Jan; 365(4):1117-29. PubMed ID: 17101149
[TBL] [Abstract][Full Text] [Related]
20. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
